In The News

Myval associated with no device-related mortality at one year

January 03, 2020

One-year data for the Myval transcatheter aortic valve implantation (TAVI) system indicate it is associated with 100% freedom from device related mortality at one year.

In The News

TCT 2019: Low rate of MACE at 12 months with “world’s thinnest stent”

December 28, 2019

K Sivaprasad (Govt TD Medical College, Alappuzha, India) reported at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA) yesterday that the Evermine 50 stent (Meril Life), which has a strut thickness of 50μm, is associated with a low rate of major adverse events (MACE) at 12 months.

In The News

Thin-Strut Bioresorbable Vascular Scaffold Shows Promise

December 27, 2019

The MeRes 100 thin-strut sirolimus-eluting bioresorbable scaffold, developed by Meril Life Sciences, demonstrated zero scaffold thrombosis and very low major adverse cardiac event rates for up to three years, according to two recent clinical trials.


Founded in 2006, Meril is an India-based global medical device company that is dedicated to the innovation, design and development of novel, clinically relevant and state-of-the-art devices